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Abstract 
 
Imprinting disorders (ImpDis) are a group of currently twelve congenital diseases with 
common underlying (epi)genetic aetiologies and overlapping clinical features affecting 
growth, development and metabolism. In the last years it has emerged that ms are 
characterized by the same types of mutations and epimutations, i.e. uniparental disomies, 
copy number variations, epimutations, and point mutations. Each ImpDis is associated with a 
specific imprinted locus, but the same imprinted region can be involved in different ImpDis. 
Additionally, even the same aberrant methylation patterns are observed in different 
phenotypes. As some ImpDis share clinical features, clinical diagnosis is difficult in some 
cases. The advances in molecular and clinical diagnosis of ImpDis help to circumvent these 
issues, and they are accompanied by an increasing understanding of the pathomechanism 
behind them. As these mechanisms have important roles for the etiology of other common 
conditions, the results in ImpDis research have a wider effect beyond the borders of ImpDis. 
For patients and their families, the growing knowledge contributes to a more directed genetic 
counselling of the families and personalized therapeutic approaches. 
 
Key-words: Imprinting Disorder – epigenetic regulation – imprinted genes network – 
uniparental disomy 
 
Abbreviations: 
 
CNV – copy number variation 
DMR – differentially methylated region 
ImDis – imprinting disorder 
IGN – imprinted genes network 
IUGR – intrauterine growth retardation 
MZ - monozygotic 
PNGR – postnatal growth retardation 
SNP – single nucleotide polymorphisms 
TF – transcription factor 
UPD – uniparental disomy 
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Introduction 
 
Imprinting disorders (ImpDis) are a group of congenital disorders caused by common types of 
alterations affecting imprinted genes or chromosomal regions. Though the pathophysiological 
mechanisms are unclear for the majority of ImpDis associated features, it is generally 
accepted that they all lead to an imbalance of the fine-tuned expression of genes regulated by 
differentially methylated regions (DMRs) in imprinted chromosomal regions. The molecular 
changes are heterogeneous in several ImpDis (table 1), and not only comprise different types 
of alterations at the same locus, but also different loci and/or chromosomes can be affected in 
the same ImpDis. 
 
The molecular pathology in ImpDis comprises genomic as well as epigenetic changes (figure 
1). In contrast to the majority of biallelically expressed genes, imprinted genes are expressed 
monoallelically and dependent from the parental origin of the allele, i.e. either the maternal or 
the paternal allele is expressed. At the molecular level, the expression of genes within 
imprinted regions is influenced by methylation of CpG residues in the genomic DNA 
(organised in differentially methylated regions – DMRs), interference with non-coding RNAs 
(ncRNAs), changes in chromatin structure, and post-translational histone modifications. So 
far, more than 90 imprinted human genes have been identified, but there are probably more 
(for review: http://www.geneimprint.com/site/home, last check: April 2016). The epigenetic 
signature of the human genome is inherited from the parental gametes and is then maintained 
in the majority of somatic cells and tissues of an individual. Genomic imprinting marks are 
exempted from the general developmental reprogramming of methylation marking; instead, 
they are erased in the germ-line and re-established according to the sex of the contributing 
parent for the next generation. Many genes regulated by genomic imprinting are found in 
clusters, i.e. imprinted loci often comprise multiple genes under a coordinated control.  
  
Clinical Pictures 
 
To date, twelve ImpDis have been defined (table 1) based on distinct clinical findings and/or 
an association with molecular disturbances at specific imprinted loci. The majority of ImpDis 
show features belonging to common clinical groups, i.e.: 
- aberrant pre- and/or postnatal growth, 
- hypo- or hyperglycemia, 
- abnormal feeding behavior in early childhood and later, 
- behavioural difficulties, mental retardation, 
- precocious puberty. 
However, the distinction between the different ImpDis becomes sometimes difficult due to 
common phenotypic signs and overlapping molecular alterations (1), which can pose 
problems for accurate diagnosis in some patients. Clinical scoring systems are available for 
some ImpDis (table 2), and define typical phenotypic features for these disorders, but might 
fail to detect those patients with only minor or atypical clinical signs. Furthermore, even the 
cases satisfying the clinical diagnostic criteria for a specific ImpDis can carry a molecular 
change typically associated with another ImpDis. 
Nearly all ImpDis patients are diagnosed in (early) childhood. However, clinical diagnosis is 
often hampered by the breadth of the phenotypic features which are sometimes subtle, 
overlapping and transient. The latter can obscure diagnosis in puberty and adulthood. As a 
consequence, an unknown number of ImpDis patients are probably either mis- or 
undiagnosed. Additionally, the clinical ambiguity can make the decision of the applicable test 
difficult.  
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Common molecular alterations 
 
So far, four different types of molecular changes have been shown to be associated with 
ImpDis, (i) copy number variations (CNVs: deletions,  duplications) of the imprinted region, 
(ii) uniparental disomy (UPD), (iii) aberrant methylation marks (“epimutations”), and (iv) 
point mutations in (imprinted) genes. With the exception of point mutations which directly 
affect the function of the relevant gene product, the functional relevance of these changes can 
only be estimated: as mentioned before, they probably affect the finely-balanced expression of 
imprinted factors, but the detailed pathophysiology is not yet established for the majority of 
disorders. 
 
(i) CNVs were the first alterations detected in ImpDis and are extremely valuable to identify  
and delineate the genomic regions of imprinted factors and regions. The first examples were 
15q deletions affecting either the maternally or paternally inherited allele in Angelman and 
Prader-Willi syndromes, respectively (2). The significance of CNVs of different sizes to 
understand the hierarchical regulation of DMRs in the same chromosomal region is illustrated 
by the MEG3 and IG-DMRs in 14q32, where the IG-DMR is dominant over the MEG3 DMR 
(3, 4). After identification of imprinted genomic regions, the detailed characterization of small 
CNVs therein contributes to the identification of sequences involved in the setting of 
imprinting marks (e.g. (5)). 
 
(ii) The second class of mutations typically associated with ImpDis is uniparental disomies 
(UPD), i.e. the inheritance of both chromosomes/chromosomal regions of a pair from only 
one parent (6).  The first UPD reported in human was a upd(7)mat in a Cystic Fibrosis patient 
with an unexpected homozygosity for an autosomal-recessive CFTR mutation (7). The patient 
also exhibited clinical features of Silver-Russell syndrome (SRS), but the link between 
upd(7)mat and SRS was not established until 1995 (8). The first association between UPD of 
an imprinted region and a specific phenotype was published in 1989 for Prader-Willi 
syndrome (2).  
The first reports on UPD illustrated the two subtypes of UPD. Upd(7)mat is an example of 
uniparental isodisomy (UPiD), i.e. two identical copies of the same chromosome have been 
inherited; homozygosity for an autosomal-recessively inherited disorders can result, as in the 
case of Spence et al. (7). The other UPD subtype is uniparental heterodisomy (UPhD), i.e. 
inheritance of both chromosomes from the same parent. Different modes of UPD formation 
have been postulated, all resulting from meiotic and/or mitotic nondisjunction mechanisms 
(for review: (8)). The major mode of UPD formation is trisomic rescue, which mainly results 
in UPhD of the whole chromosome or a mixed UPhD/UPiD. In contrast, pure UPiD is often 
caused by postzygotic nondisjunction. Both UPiD and UPhD result in the same 
pathophysiological effects when they affect the expression of imprinted genes. Indeed, with 
the exception of the central precocious puberty-2, Schaaf-Yang syndrome and Birk-Barel 
mental retardation, UPD has been identified in all ImpDis. The contribution of UPD to the 
mutation spectrum in ImpDis ranges between 1% (in Angelman syndrome, AS) and nearly 
80% (in Temple syndrome, TS14). UPDs contribute to the identification of imprinted 
chromosomes, but in contrast to CNVs affecting imprinted genes, UPD often comprise whole 
chromosomes or large segments (“segmental UPD”) and therefore they have not been helpful 
for the identification of imprinted genes or regions.  
 
(iii) The term “epimutation” describes an aberrant DNA methylation or histone modification 
pattern at a DMR without a disturbance of the genomic DNA sequence at the respective 
DMR. Primary epimutations are defined as isolated alterations of an imprinting mark, without 
any obvious associated DNA sequence alteration, whereas secondary epimutations are the 
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result of a DNA sequence change outside the DMR (for review: (9)). In BWS primary 
epimutations at the ICR2 DMR have been associated with the use of assisted reproductive 
technologies (10). There is a growing number of reports on genomic mutations which cause 
secondary epimutations at an imprinted locus. These genomic variants comprise both CNVs 
or point mutations in direct neighborhood to the DMR (cis acting) as well as variants in other 
chromosomal regions (trans acting) (figure 2).  
 
iv) Point mutations in protein-coding genes have been reported only in five of the 10 known 
ImpDis; with exception of central precocious puberty-2 (PPS2) and Birk-Barel mental 
retardation they account only for a small number of patients or single cases (table 1). It should 
be noted that they are the only class of variants in ImpDis which likely directly cause 
characteristic features. Nevertheless, even in this group of molecular defects the pathogenetic 
mechanisms are not yet understood. 
 
Peculiarities in genetics of Imprinting Disorders 
 
Imprinting disorders are genetically caused syndromes, but show several differences in 
comparison to classical Mendelian inherited diseases. 
When familial, inheritance of CNVs and point mutations is usually autosomal dominant, but 
the penetrance of the mutation depends on the sex of the parent contributing the molecular 
alterations. Typical examples are MKRN3, MAGEL2, KCNK9, UBE3A, CDKN1C and IGF2 
mutations which result in a pathological phenotype only if the active maternal or paternal 
allele is affected. Genetic counselling becomes even more complex in case of chromosomal 
translocations predisposing to a deletion or duplication of an imprinted region because 
different ImpDis can be expected. Additionally, this situation can be complicated by the 
(theoretical) risk of UPD formation (e.g. (11)). 
 
A further common molecular finding in some ImpDis is mosaicism. It is observed in patients 
carrying UPiD and epimutations, and can be explained by the mainly post-zygotic origin of 
these changes. Mosaicism can obscure genotype-phenotype correlation, and can significantly 
hamper the detection and diagnosis of both disturbances.  
 
The third ImpDis-specific observation is discordant monozygotic (DMZ) twinning, which has 
particularly been reported in BWS (for review (12)). This discordance is remarkable because 
MZ twins derive from the same zygote and are therefore genetically identical. However, it 
may be regarded as a phenomenon related to epigenetic mosaicism: an early embryo with 
marked mosaicism between different cells may develop into a single mosaic individual, or if 
the embryo fragments, it may develop into monozygotic twins with different degrees of 
epimutation.  The frequency of DMZ twinning is several-fold higher in cases of BWS, TNDM 
and MLID (see below) than in the general population (12-14).  It is currently unclear whether 
hypomethylation predisposes to DMZ twinning or vice versa. Interestingly, there is a 
considerable preponderance of females among the MZ twins with BWS, and a functional link 
between altered imprinting and X chromosome inactivation has been suggested (15). 
 
Advances in Imprinting Disorders I: Identification of new Disorders 
 
Whereas Prader-Willi, Angelman, Beckwith-Wiedemann and Silver-Russell syndromes, 
transient diabetes mellitus, and pseudohypoparathyroidism Ib (PWS, AS, BWS, SRS, TNDM 
and PHPIb) are well known as ImpDis, five further ImpDis have been defined recently and 
will be overviewed in the following paragraph (table 1). 
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Two of the new syndromes are associated with the chromosomal region 14q32, and were 
firstly described as upd(14)mat and upd(14)pat syndromes. More recently, additional 
molecular changes have been reported, and therefore the names Temple syndrome (TS14) 
for upd(14)mat and Kagami-Ogata syndrome (KOS14) for upd(14)pat have been proposed 
(1, 4). In both syndromes at least two DMRs are involved (MEG3/DLK1:IG-DMR and 
MEG3:TSS-DMR), and the role of a third has been proposed  (16). TS14 and KOS14 result 
from opposing molecular changes –effectively maternalisation and paternalisation 
respectively – at the chr14 DMRs.  Pairs of syndromes caused by opposing molecular changes 
are also seen at 15q11q13 in PWS/AS and 11p15.5 in SRS/BWS. For TS14, the role of an 
altered RTL1 and DLK1 expression has been suggested (4). In case of Kagami-Ogata 
syndrome it has been postulated that the increased expression of RTL1 regulated by the 
MEG3/DLK1:IG-DMR is responsible for the clinical outcome, whereas a role of DLK1 can be 
discounted (4). The expression of these genes is hierarchical and primarily regulated by the 
MEG3/DLK1:IG-DMR, whereas the MEG3:TSS-DMR is subordinate (3, 4). 
 
Mutations in KCNK9 (8q24.3) have been reported in individuals with Birk-Barel mental 
retardation (17) with the phenotype manifesting only after maternal transmission, consistent 
with the gene’s imprinting status (18). This disorder is associated with moderate to severe 
intellectual disability, hyperactivity, feeding difficulties, hypotonia at an early age and a semi-
characteristic elongated face. However screening individuals with autism-spectrum disorder, a 
disease genetically linked to the proximal 8q locus (19), or in individuals with more specific 
overlapping cognitive features failed to identify additional KCNK9 mutations or constitutive 
methylation defects of nearby PEG13 DMR (20). Together this suggests that the maternally-
inherited KCNK9 mutations cause the phenotype through a dominant-negative effect with 
other potassium channel proteins in the brain.  
Central precocious puberty 2 (CPP2) has recently been identified as an isolated feature 
caused by genomic variants in the Makorin ring finger 3 (MKRN3) gene (21-24): Consistent 
with the MKRN3 imprinting status the phenotype is only present in case of paternal 
transmission of the mutation. Mutations in MKRN3 have been shown to be the most frequent 
cause of familial CPP and they have also been detected in nearly 4% in a cohort of 215 non-
familial idiopathic CCP (21). The MKRN3 gene (also known as ZNF127) is an intronless 
transcript located on chromosome 15q11.2 in the PWS critical region, encoding a protein with 
C3H zinc-finger and RING zinc-finger motifs. In contrast to the broad molecular spectrum 
associated with other ImpDis, genomic point mutations of MKRN3 are currently the only type 
of variants associated with CPP2. 
The same chromosomal region is associated with another recently suggested ImpDis, the 
Schaaf-Yang syndrome (SHFYNG)(25). The disorder is caused by heterozygous mutations 
in the MAGEL2 gene which occur on the paternal allele. Clinically, the phenotype resembles 
PWS. 
 
Maternal uniparental disomy of chromosome 20 (upd(20)mat) has been reported in twelve 
patients (26), three of whom also had mosaicism for complete or partial trisomy of 
chromosome 20. So far, other types of molecular alterations have not been described, and a 
candidate region on chromosome 20 is currently unknown. The prevalence of upd(20)mat is 
currently unknown; one reason is probably the lack of specifity of its major clinical features, 
i.e. failure to thrive and intrauterine/postnatal growth retardation. In particular, dysmorphisms, 
congenital abnormalities or major developmental delay have not yet been reported that might 
contribute to a further clinical definition of the disorder. Upd(20)mat has been identified in 
single patients referred with features of SRS or TS14; thus these cohorts may contain other 
individuals with upd(20)mat as a significant phenotypic overlap exists.  
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Advances in Imprinting Disorders II: Towards an understanding of the 
pathomechanisms in Imprinting Disorders 
 
With the continuous improvement of diagnostic methods and the extensive molecular 
characterisation of ImpDis patient cohorts and mouse models, there is an increase of newly 
identified molecular alterations and (imprinted) genetic loci associated with ImpDis 
phenotypes. Not all new findings in the field of ImpDis can be described in this review, but 
we will focus on factors belonging to the 11p15.5 imprinting regions and their interaction 
partners. 
In the last decade it has emerged as a general observation that many imprinted genes belong 
to common functional networks, either because of their physiological function or because they 
belong to the so-called imprinted genes network (IGN) (for review: (27)). Gene networks are 
derived from linked data associated with complex gene function and phenotypes. These 
networks combine massive transcriptome data sets and gene variants revealing genetic 
modifiers that modulate spatial and temporal expression of core developmental networks. 
This ultimately reflects coordinated mRNA synthesis via shared transcription factors (TFs), 
mRNA stability, mRNA translation, and protein stability. 
 
As outlined earlier, there is considerable clinical and molecular overlap between different 
ImpDis, which might be explained by the proposed IGN presided by the zinc-finger TF 
PLAGL1 which is co-expressed with hundreds of genes, many of which are imprinted (28). 
These include H19, IGF2 and CDKN1C in both mouse and humans (figure 3)(28, 29). Modest 
changes in the abundance or activity of a single TF such as PLAGL1 could result in the altered 
expression of downstream targets, including the ImpDis-associated genes H19 and CDKN1C 
resulting in an effect of PLAGL1 on the SRS and BWS phenotypes. Furthermore an additional 
imprinted zinc-finger TF Peg3 also exhibits transactivation on multiple genes (30), including 
GRB10 an imprinted gene associated cytogenetic aberrations in SRS (31). 
Gene regulation is not a linear process, but rather occurs in the context of complex networks 
of interactions between multiple genes and mechanisms, which encompass TFs and post-
transcriptional regulation. This is highlighted in the case of IGN, in which the TF PLAGL1 
influences the expression of the H19 ncRNA, which itself acts as microRNAs (miRNA) 
sponge antagonizing numerous miRNAs (32) and encodes for miR-675 which would have an 
augmenting effect on target mRNAs (33).  Consistent with this interactive IGN, numerous 
imprinted genes on different chromosomes, including Gnas, Rtl1, Dlk2 and IGF2r are 
deregulated in mice carrying maternal deletions of H19 (34). Interestingly PLAGL1 
expression levels remained constant in this model. 
Recently, additional networks regulating growth associated imprinted genes have been 
described, including the role of unoccupied insulin and insulin-like growth factor 1 receptors 
(35)(figure 3). This novel non-canonical mechanism is also independent of PLAGL1 despite 
influencing many of the same target genes, suggesting that the IGN can be subdivided into 
smaller interconnected ‘hubs’ (36).  
 
Finally the paternally expressed ncRNA IPW located in the PWS region on chromosome 15 
regulates the levels of maternally expressed transcripts within the imprinted cluster on 
chromosome 14 (37). The trans-acting repression of the DLK1-DIO3 locus by IPW involves 
the recruitment of the H3K9 histone methyltransferase G9a to the chromosome 14 imprinting 
control regions, the IG-DMR. These observations support the rapidly expanding theory that 
the IGN influences clinical features associated with ImpDis, highlighted by individuals with 
TS14 who display PWS-like phenotypes (38). It remains to be determined if these co-
expressed imprinted loci interact with in the nucleus, giving the IGN a physical dimension 
which may occurs if they share common transcriptional factories. 
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Trans acting mechanisms are also the basis for the observation that genomic mutations in 
factors such as NRLPs and ZFP57 are associated with multi-locus imprinting disturbance 
(MLID).  Loss of function mutations of ZFP57 have been found in TNDM cases with MLID 
(39). In the mouse, Zfp57 interacts with a specific target sequence in the methylated alleles of 
the ICRs, and its inactivation leads to loss of methylation at multiple imprinted loci (40, 41).  
Strikingly, while mouse Zfp57 is associated with both imprinted and non-imprinted DMRs, it 
associates preferentially with Zac1 and Peg3, mirroring the loci commonly affected in human 
patients with ZFP57 mutations (42). NLRP mutations identified to date are maternal-effect, 
i.e. mutations in mothers are associated with MLID in their offspring.  Maternal-effect NLRP7 
mutations are associated with hydatidiform moles, a pregnancy outcome with paternalisation 
of imprinting, which is incompatible with life (43, 44).  Maternal mutations of NLRP2 and 
NLRP5 have been associated with MLID in liveborn offspring (13, 45), though, interestingly, 
the clinical features and epimutations in affected children are not consistent, suggesting that 
these mutations disrupt imprinting stochastically.  Likewise, methylation patterns vary in 
hydatidiform moles caused by NLRP7 mutation (20).  However, hydatidiform moles show 
extreme hypomethylation of maternal imprinting marks only, whereas NLRP5 mutations 
cause mosaic hypomethylation affecting both maternal and paternal marks, suggesting that 
NLRP7 may exert its effect in the oocyte, while NLRP5’s action may be postzygotic.  The 
inter-species variability and high similarity of genes in the NLRP cluster will pose challenges 
for disentangling their roles in ImpDis.  However, the identification of KHDC3L and TLE1 
mutations impacting reproductive fitness (46, 47) suggests that maternal-effect genes may in 
future be implicated more widely in imprinting, epigenetics and development. 
 
Advances in Impriting Disorders III: Improvement of molecular diagnostics 
 
Until recently, molecular testing for ImpDis was restricted to single disease-specific loci. The 
detection rates at least in PWS, AS, SRS, and BWS are more or less well established (table 1), 
but technical, biological and clinical factors influence the diagnostic yield of the available 
assays.  
A broad range of molecular tests are available (for review: (48)), but their different 
sensitivities and the lack of standardization make a comparison of the molecular results 
between different studies difficult. Furthermore mosaicism hampers molecular ImpDis 
testing. It frequently occurs in patients carrying UPiD and epimutations, and can be explained 
by the mostly post-zygotic origin of these changes. The level of mosaicism can show a broad 
range, and sometimes differs remarkably between different tissues (49). The limited 
sensitivity of current single-locus tests might therefore restrict their diagnostic yield. 
However, the identification and discrimination of the molecular ImpDis subtype is required 
for a precise molecular diagnosis and a well-directed genetic counselling. 
 
The broadening of molecular testing in the last years has shown that there is a considerable 
overlap between the different ImpDis, and the application of single-locus test can preclude the 
diagnosis of basic molecular defects and might leave a patient without diagnosis (50). The 
application of tests aiming on different imprinted loci in ImpDis diagnostics allows the 
identification of unexpected molecular findings and circumvents the decision to apply a locus 
specific test in this group of overlapping and heterogeneous clinical pictures. Furthermore, a 
considerable number of ImpDis patients exhibit aberrant methylations at different imprinted 
loci (MLID) (49). These patients might show a broad clinical spectrum and the phenotype can 
be ambiguous or even atypical for one of the known ImpDis.  
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
One major prerequisite for the future comprehensive diagnostic analysis of ImpDis loci is the 
identification and definition of a standardized set of imprinted loci, DMRs and CpG islands 
(for review: (48). The first step has been undertaken by the European network of imprinting 
disorders EUCID.net with the introduction of common ImpDis names and abbreviations, and 
the LRG/HGV-based naming of DMRs and definition of their physical positions (see 
www.imprinting-disorders.eu). To make the huge number of mutations and epimutations from 
different diagnostic and research institutions available to the public, the common use of 
LOVD (Leiden open variation database) as the common variation database is suggested 
(http://www.lovd.nl/3.0/home) and has been initiated by EUCID.net.  
An increasing number of studies show that the aforementioned problems in diagnosis and 
investigation of ImpDis can be diminished by the use of new tests targeting multiple loci 
and/or a total exome and genome analysis. Deep-sequencing NGS assays are in development 
for these purposes, and it has been shown that NGS is able to detect even low-level mosaicism 
(3, 5).  
 
Advances in ImpDis IV: clinical diagnosis, genetic counselling and treatment 
 
With the increasing knowledge on the molecular basis and clinical spectrum of ImpDis and 
the improved molecular testing strategies, the foundation stone is laid for a more directed 
genetic counselling of the families and personalized therapeutic approaches.  
However, like for the molecular nomenclature, the use of a controlled and standardized 
vocabulary for describing clinical entities is required in the clinical diagnosis of ImpDis, as it 
is now provided by HPO (human phenotype ontology, http://www.human-phenotype-
ontology.org/). This HPO nomenclature is the basis for a common phenotyping questionnaire, 
which is now also provided as a common phenotyping tool by the EUCID.net.  
 
Despite or even because of the increasing reports on heterogeneous molecular findings in the 
majority of ImpDis, it is emphasized that the diagnosis of nearly all ImpDis is a primarily 
clinical diagnosis, but that molecular testing allows confirmation and the identification of the 
molecular subtype which is a prerequisite for a specific clinical management (e.g. tumour 
surveillance in BWS). Furthermore, a normal test result does not exclude the diagnosis of an 
ImpDis but differential diagnoses with divergent clinical consequences and recurrence risks 
have to be considered (for differential diagnosis of the different IDs we suggest to seek advice 
from the ImpDis -specific literature listed in table 2). However, due to their clinical 
heterogeneity the diagnosis of ImpDis is often difficult as many features are non-specific. 
This results in a large and often undirected and arbitrary number of molecular tests in patients 
with only few ImpDis features, and vice versa in a low diagnostic yield (e.g. (51)). Thus, at 
least for the more frequent IDs clinical scoring systems have been proposed (table 2), but the 
increasing numbers of suggested scores in some IDs and their low acceptance and limited 
application illustrate the uncertainty of clinicians to use them. The general acceptance of the 
Netchine-Harbison-Score for SRS (52) by the SRS consensus group in 2015 and the 
development of tests for BWS and PHP by similar consensus activities organized by the 
EUCID.net hopefully will solve this problem and will contribute to a common clinical 
diagnosis of ImpDis. These approaches towards a common language in ImpDis and their 
diagnosis are complemented by the drafting of clinical utility gene cards (CUGC), 
GeneReviews, and recently by the first interdisciplinary diagnostic and clinical consensus 
guidelines (table 2). 
 
All these activities aim to facilitate the daily work in clinical diagnosis and genetic 
counselling of patients and families suspicious for ImpDis. In case the clinical diagnosis can 
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be confirmed by molecular testing, a careful characterization of the molecular disturbance is 
required to determine the molecular subtype and its potential to be inherited.  
In case of a positive testing result, different recurrence risks can be delineated (table 1), which 
are not only influenced by the type of alteration but also by the sex of the parent who 
contributes the affected allele. For UPD, the recurrence risk is generally low but differs 
among the ImpDis: whereas it can be neglected in BWS as upd(11p)pat originates from 
postzygotic mitotic errors, in case of chromosomes 14 and 15 it can increase because it might 
be caused by a (familial) translocation. CNVs generally harbor the potential to be caused by 
parental translocations with a significant increase of recurrent risks, also for other different 
(imprinting) disorders. The difficulty of recurrence risk determination and phenotype 
prediction in case of CNVs is not only hampered by the parental origin of the affected 
segment, but also by the size of the aberrant segment and its content of genes and regulative 
elements, as illustrated for 11p15.5 (e.g. (53)). Epimutations mainly occur sporadically and 
familial cases have rarely been reported. Thus, the recurrence risk is only slightly increased, 
with the exception of secondary epimutations caused by genomic alterations. It is also unclear 
in case of MLID, here families with maternal effect mutations in NLPR genes have been 
reported, and NLRP mutation carrier women are at an increased risk for children with 
aberrant DMR methylation.  
 
Conclusions and Outlook 
 
The last years have seen a significant progress in deciphering molecular causes and 
pathomechanisms of ImpDis, to better understand the complex interactions between imprinted 
loci and thereby regulated factors. The application of new high-throughput technologies and 
deep phenotyping approaches will contribute to a comprehensive and improved diagnostic 
yield as a significant step towards personalized therapeutic managements.  
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Figures and Tables 
 
Table 1 
Disorder Chromosome Molecular 
Alterations 
Frequencies MLID recurrence risk Clinical features 
Transient Neonatal Diabetes 
mellitus  (TNDM) 
6q24 UPD(6)pat 41%   <1% IUGR, transient diabetes, 
hyperglycemia without 
ketoacidosis, macroglossia, 
omphalocele 
dup(6q) 29%   increased in case of a 
paternal structural 
variation 
PLAGL1:alt-TSS-
DMR: LOM 
30% 50% in case of a ZFP57 
mutation 
Silver-Russell syndrome 
(SRS) 
7 upd(7)mat 7-10% 1 case <1%, but a single familial 
structural variation has 
been reported 
IUGR/PNGR, relative 
macrocephaly, asymmetry, 
G1prominent 
forehead/triangular face, 
feeding difficulties CNVs (dup7p), 
del7q 
single cases   increased in case of a 
familial structural 
variation 
11p15.5 upd(11)mat n=1 - <1% 
dup(11p15)mat 1-2% - increased in case of a 
familial structural 
variation 
H19/IGF2:IG-
DMR: LOM 
>38%  ~10% only single families, risk 
might be increased in 
case of MLID 
CDKN1C 
mutations 
n=1 - 50% in case of maternal 
transmission 
IGF2 mutations n=1 - 50% in case of paternal 
transmission 
Birk-Barel mental 
retardation 
8q24.3 KCNK9 mutations unknown - 50% in case of maternal 
transmission 
intellectual disability, 
hyperactivity, feeding 
difficulties, hypotonia, 
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elongated face 
Beckwith-Wiedemann 
syndrome (BWS) 
  upd(11)pat 20% - no pre- and postnatal 
overgrowth, organomegaly, 
macroglossia, 
omphalocele, neonatal 
hypoglycemia, 
hemihypertrophy, 
increased tumour risk 
    uniparental 
diploidy* 
~ 10%?   
    paternal UPD ~  90%   
dup(11p15)pat 1-2% - increased in case of a 
familial structural 
variation 
H19/IGF2:IG-
DMR: GOM 
4% - 20%+F28 (in case of 
microdeletions or SNPs 
in the OCT4/SOX2 
binding site) 
KCNQ1OT1:TSS-
DMR: LOM 
50% 25% only single families have 
been reported, but the 
risk might be increased 
shen  MLID 
CDKN1C 
mutations 
5% - 50% in case of maternal 
transmission 
Temple syndrome 
(UPD(14)mat) 
14q32 upd(14)mat 78.4% - <1%, but increased in 
case of familial 
Robertsonian 
translocation 
IUGR,PNGR, hypotonia, 
feeding difficulties in 
infancy, truncal obesity, 
scoliosis, precocious 
puberty del(14q32)pat 9.8% - <1%, but increased in 
case of familial 
translocation 
MEG3/DLK1:IG-
DMR and 
MEG3:TSS-DMR: 
LOM 
11.7% NR unknown 
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Kagami-Ogata syndrome 
(UPD(14)pat) 
upd(14)pat 65.4% - <1%, but increased in 
case of familial 
Robertsonian 
translocation 
IUGR, polyhydramnion, 
abdominal and thoracal 
wall defects, bell-shaped 
thorax, coat-hanger ribs 
del(14q32)mat 19.2% - <1%, but increased in 
case of familial 
translocation 
MEG3/DLK1:IG-
DMR and 
MEG3:TSS-DMR: 
GOM 
15.4% NR   
Angelman syndrome (AS) 15q11q13 UPD(15)pat 1-2% - <1% mental retardation, 
microcephaly, no speech, 
unmotivated  laughing, 
ataxia, seizures 
del(15q11q13)mat 75% - <1%, but increased in 
case of familial 
translocation 
SNURF:TSS-
DMR: LOM 
~3% - Up to 50% 
UBE3A mutations 5-10% - Up to 50% 
Prader-Willi syndrome 
(PWS) 
upd(15)mat 25-30% - <1% PNGR, mental retardation, 
neonatal hypotonia, 
hypogenitalism, 
hypopigmentation, obesity/ 
hyperphagia 
del(15q 11q13)pat 70-75% - <1%, but increased in 
case of familial 
translocation 
SNURF:TSS-
DMR: GOM 
~1%+D43 1 case Up to 50% 
Precocious puberty 15q11.2 MKRN3 mutations unknown - 50% in case of paternal 
transmission 
Precocious puberty (girls: 
5.75 years, boys: 8.10 
years) 
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Schaaf-Yang syndrome 
(SHFYNG) 
15q11.2 MAGEL2 
mutations 
unknown - 50% in case of paternal 
transmission 
neonatal hypotonia, feeding 
problems in infancy, then 
hyperphagia, 
developmental delay, 
hypogonadism 
Sporadic 
Pseudohypoparathyreoidism 
Ib 
20q13 upd(20)pat 10-25% - <1% resistance to PTH and 
other hormones, Albright 
hereditary osteodystrophy, 
subcutaneous ossifications, 
feeding behaviour 
anomalies, abnormal 
growth  
del(20q13) rare   <1%, but increased in 
case of familial 
translocation 
GNAS-
NESP:TSS-DMR: 
LOM 
GNAS-XL:Ex1-
DMR: LOM 
GNAS A/B:TSS-
DMR 
>60% 12.5% <1% 
upd(20)mat 20 upd(20)mat unknown 9 cases <1%?, but familial 
translocation should be 
considered 
IUGR, PNGR, failure to 
thrive 
 
 
Table 1  Overview on the molecular and clinical findings in the currently known ImpDis. (IUGR intrauterine growth retardation; 
PNGR postnatal growth retardation; LOM loss of methylation; GOM gain of methylation; PTH parathormone; *paternal uniparental disomy: all 
chromosomes are affected (formerly named genomewide UPD)) 
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Table 2 
ImpDis OMIM 
Clinical Scoring systems/ 
clinical diagnosis CUGC GeneReviews®
Molecular 
 Guidelines
Clinical guidelines/ 
Consensus guidelines 
TNDM 601410 NA (60) yes NA NA 
SRS 180860 (52) (70) yes (50) in preparation 
BB-MR 612292 NA NA NA NA NA 
BWS 130650 (54, 55) (62) yes (50) in preparation 
TS14 616222 (58) NA NA NA NA 
KOS14 608149 (59) NA NA NA NA 
PWS 176270 (56) (63) yes (66) (68) 
AS 105830 NA (64) yes (66) NA 
PPS-2 615346 NA NA NA NA NA 
SHFYNG 615547 NA NA NA NA NA 
PHPIb 603233 (57) (65) (57) (67) in preparation 
upd(20)mat NA (26) NA NA NA NA 
 
 
Table 2  Diagnostic, clinical and management guidelines published for ImpDis. (*http://www.ncbi.nlm.nih.gov/books/NBK1116/; 
CUGC clinical utility gene cards; NA not available) 
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Primary epimutation
Disturbed balance
of imprints
Mutation/CNV of
a non-imprinted
gene ImpDis or
ImpDis-like phenotype
Molecular changes
affecting DMRs
Fig. 1 Secondary epimutation
cis- or trans
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UPD
aberrant expression
Contribution to
the phenotype
Epimutation CNV
Mutation in the
imprinted gene itself
 
Figure 1  Schematic overview on the currently known molecular alterations and 
their functional consequences leading to ImpDis and ImpDis-like phenotypes.  
Fig. 2
Paternal
chromosome
H19 IGF2 Maternalchromosome
IGF2
ICR1
H19/IGF2: IG-DMR
cis acting enhancers
trans acting factors
 
Figure 2  Illustration of the influence of cis-acting elements and trans-acting 
factors on imprinted genes and their expression for the imprinted region in 11p15. 
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Fig. 3
 
Figure 3  Exemplary illustration of the physiological interaction between 
imprinted and not imprinted genes affecting growth. The different interactions are 
summarized from numerous studies in mice and human tissues, thus the capitalization of the 
gene names is not linked with a specific organism. (blue paternally expressed genes, red 
maternally expressed genes, white not imprinted, blue and red stripes gene with tissue and 
species specific and opposite imprinting; red lines inhibitory effect, green arrow promoting 
effect).  
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